Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
Open Access
- 28 November 2016
- journal article
- case report
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 497
Abstract
Male breast cancer is a rare event, accounting for approximately 1% of all breast carcinomas. Although men with breast cancer had poorer survival when compared with women, data on prognosis principally derive from retrospective studies and from extrapolation of female breast cancer series. We reported the case of a very long survival patient. A caucasian 42-year-old man underwent radical mastectomy with axillary dissection for breast cancer in 1993. Pathologic stage was pT4pN0M0 infiltrating ductal carcinoma of right breast without lymph nodes metastases. Biological characterization was not available. He received adjuvant treatment with chemotherapy, six cycles of cyclophosphamide, methotrexate and fluorouracil, then endocrine therapy with tamoxifen for 5 years and complementary radiotherapy. Then he began clinical-instrumental follow up. In May 1996, a computed tomography scan showed multiple lung metastases. Hereafter he received several oncologic treatment including seven chemotherapy and five endocrine therapy lines with two re-challenge of endocrine therapy. In October 2007 further lung progression was showed and a biopsy was performed to characterize the disease. Histological examination confirmed breast cancer metastases, immunohistochemistry showed positive staining for estrogen receptor, negative for progesterone receptor and human epithelial growth factor receptor 2, proliferative index was 21%. In April 2013, bone disease progression was evident and he received radiant treatment to sacral spine. In May 2014 an off-label treatment with exemestane and everolimus combination was approved by Ethics Committee of the Marche Region. The patient received treatment for 3 months with evident clinical benefit to subcutaneous lesions of the chest wall that were not visible nor palpable on physical examination after 1 month of treatment. That is the case of long survival male breast cancer patient with luminal B subtype and no BRCA mutations. He achieved higher progression free survival with endocrine therapy creating the rationale for last line treatment with everolimus and exemestane combination. Attending conclusive results from ongoing studies, everolimus and exemestane should not be used routinely in male metastatic breast cancer patients, but taking into account for selected cases. At the best of our knowledge, this is the first case of male beast cancer treated with exemestane and everolimus combination.Keywords
This publication has 22 references indexed in Scilit:
- Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancerBreast Cancer Research and Treatment, 2013
- Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trialSupportive Care in Cancer, 2013
- Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factorsEuropean Journal of Cancer Care, 2012
- Male breast carcinoma: increased awareness neededBreast Cancer Research, 2011
- Aromatase inhibition in male breast cancer patients: biological and clinical implicationsAnnals of Oncology, 2009
- The rising incidence of male breast cancerBreast Cancer Research and Treatment, 2008
- Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancerJournal of Surgical Oncology, 2005
- Breast carcinoma in menCancer, 2004
- Rémission complète par létrozole chez un homme traité pour un cancer du sein métastatiqueLa Revue de Médecine Interne, 2004
- An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patientsSurgery, 1999